Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observed Mealtime Interactions, Meal Healthfulness, and Childhood Obesity Among Low-Income Families.

Pediatric obesity·2026
Same author

Comparing neuroprotective drug efficacy in rodent neonatal brain injury models.

Pediatric research·2026
Same author

Mobile Health Unit Outreach to Socially Disadvantaged Urban Communities Detects Uncontrolled Cardiometabolic Risk Factors.

Journal of the American Heart Association·2026
Same author

Blood Pressure Trajectories Among Adults Living in Extreme Poverty: A Population-Based Cohort in Port-au-Prince, Haiti.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Increased Density of Mobile Health Unit Encounters Among Primary Care Health Professional Shortage Areas.

International journal of environmental research and public health·2026
Same author

Bedroom Air Filtration and Home Blood Pressures of Older Adults Living in a Residential Facility.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Relationship of Carotid-Femoral Pulse Wave Velocity and Brachial-Ankle Pulse Wave Velocity With the Risk of New-Onset Cardiovascular Events: A Cohort Study in the Beijing Community-Based Population.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Oral Health and Cardiovascular Disease Among Hypertensive Medicated Adults With Uncontrolled Blood Pressure.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Effect of Health Literacy on use of a Virtual Coach to Promote Home Blood Pressure Monitoring.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

A Clinical Prediction Model for Selective NT-proBNP Testing in Hypertension.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Effect of Body Mass Index on the Efficacy and Safety of Esaxerenone Versus Trichlormethiazide for the Treatment of Japanese Patients with Uncontrolled Essential Hypertension: A Subanalysis of the Excite-HT Study.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Factors Associated With Evidence of Self-Measured Blood Pressure Adoption in an Urban Safety-Net Health System.

Journal of clinical hypertension (Greenwich, Conn.)·2026
See all related articles
  1. Home
  3. Antihypertensive Combinations Modify Cardiovascular Risk Factor Importance: A Machine Learning Analysis Of The Accomplish Trial.
  1. Home
  3. Antihypertensive Combinations Modify Cardiovascular Risk Factor Importance: A Machine Learning Analysis Of The Accomplish Trial.

Related Experiment Videos

Antihypertensive Combinations Modify Cardiovascular Risk Factor Importance: A Machine Learning Analysis of the

Niko Kaciroti1, Phillip D Levy2,3, Kenneth A Jamerson4

  • 1Departments of Pediatrics and Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.

Journal of Clinical Hypertension (Greenwich, Conn.)
|May 14, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

The ACCOMPLISH trial found benazepril/amlodipine superior to benazepril/hydrochlorothiazide for cardiovascular protection. This combination therapy may offer benefits beyond blood pressure control, suggesting a BP-independent cardio-protective effect.

Keywords:
clinical trialscombination antihypertensive therapymachine learning

Related Experiment Videos

Area of Science:

  • Cardiology
  • Pharmacology
  • Machine Learning

Background:

  • The ACCOMPLISH trial compared benazepril/amlodipine with benazepril/hydrochlorothiazide for systolic hypertension.
  • Previous findings suggest superior cardiovascular protection with the benazepril/amlodipine combination.

Purpose of the Study:

  • To compare the relative importance of risk factors, particularly blood pressure control, in predicting cardiovascular outcomes between the two treatment groups.
  • To investigate potential blood pressure-independent cardio-protective effects of benazepril/amlodipine.

Main Methods:

  • Utilized random survival forest, a machine learning technique, to determine variable importance factors (VIFs).
  • Analyzed VIFs for risk factors, focusing on achieved systolic blood pressure at 6 months, to predict the primary composite cardiovascular outcome.
  • Compared VIFs between the benazepril/amlodipine and benazepril/hydrochlorothiazide treatment arms.

    • Main Results:

    • Six risk factors showed significantly different VIFs between the treatment groups.
    • All identified risk factors had lower VIFs in the benazepril/amlodipine group.
    • The VIF for achieved systolic blood pressure at 6 months was 35% lower with benazepril/amlodipine (0.082) compared to benazepril/hydrochlorothiazide (0.126).

    Conclusions:

    • Blood pressure control was less critical for preventing cardiovascular events with benazepril/amlodipine.
    • These findings support the hypothesis that benazepril/amlodipine offers clinically relevant cardio-protective actions independent of blood pressure reduction.
    • The study highlights the potential for combination therapy to provide benefits beyond simple blood pressure lowering.